-
WilmerHale Named Venture Capital Firm of the Year by LMG Life Sciences
9.12.2023LMG Life Sciences has named WilmerHale as the Venture Capital Firm of the Year in its 11th annual awards.
-
WilmerHale Advises Georgiamune on $75M Series A Financing
8.14.2023On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody.
-
WilmerHale Advises HawkEye 360 in $58M Series D-1 Financing
7.14.2023On July 13, 2023, HawkEye 360, Inc., the world's leading defense technology company for space-based radio frequency data and analytics, announced it has closed $58 million in new funding in a Series D-1 financing.
-
WilmerHale Advises Omeat in $40M Financing
6.27.2023On June 22, Omeat Inc., a Los Angeles-based startup, has secured $40 million in funding as it emerges from stealth mode, introducing its approach to scaling cultivated meat production.
-
WilmerHale Advises Datanomix in $12M Growth Capital
5.12.2023Gary Schall, Elijah Soko and Cindy Sullivan advised Datanomix in its recently announced financing round.
-
2023 M&A Report
3.31.2023The 2023 M&A Report provides a broad, global M&A market review and outlook, plus insights on several important topics.
-
2023 Venture Capital Report
3.31.2023The 2023 Venture Capital Report offers an in-depth US venture capital market review and outlook, including regional and industry breakdowns, along with insights on key topics.
-
2023 IPO Report
3.31.2023The 2023 IPO Report shares a detailed look at the IPO market and provides useful market metrics and need-to-know information on topics that affect pre-IPO companies.
-
2023 IPO, Venture Capital and M&A Reports
3.31.2023WilmerHale’s annual IPO, Venture Capital and M&A reports offer detailed insights into market conditions and provide comprehensive statistics and thoughtful analysis.
-
Recent Venture Financings as Company Counsel: 2023
3.9.2023In 2022, we served as counsel in more than 200 venture financings raising over $7 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Represents Volastra Therapeutics in $60M Series A Financing
3.9.2023WilmerHale represented Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), in closing its $60 million Series A financing, which was led by founding investors Polaris Partners and ARCH Venture Partners alongside Eli Lilly and Company.
-
WilmerHale Advises Dalia on Series A Financing
2.1.2023Dalia, a recruitment marketing automation platform, announced the completion of its Series A financing round led by Lewis & Clark Ventures.
-
WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing
12.8.2022On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale.
-
WilmerHale Advises Wellington Management in AMP Robotics’ $91M Series C Financing
12.8.2022On November 2, 2022, AMP Robotics, a pioneer in artificial intelligence, robotics, and infrastructure for the waste and recycling industry, announced it has raised $91 million in corporate equity in a Series C financing, led by Congruent Ventures and Wellington Management.
-
WilmerHale Advises Foodology in $50M Financing
11.21.2022Foodology, a Colombia-based virtual restaurant company, announced that it has raised $50 million in new funding, comprised of $20 million in equity and $30 million in debt.
